GO:0032027 myosin light chain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032027 (myosin light chain binding) is a molecular function defined as binding to a light chain of a myosin complex.
• Myosin light chains are essential for the structural integrity and regulatory control of myosin motors in muscle and non-muscle cells.
• The interaction between myosin heavy chains and light chains is critical for mechanosensing and force generation in cardiac muscle.
• Phosphorylation of myosin regulatory light chains modulates actomyosin dynamics and dissociation.
• Mutations in myosin light chain genes are linked to hypertrophic cardiomyopathy and other muscle disorders.
• CRISPR-based models (knockout, knock-in, point mutation) enable precise dissection of myosin light chain binding in health and disease.
Description
Myosin light chain binding (GO:0032027) is a molecular function that mediates the specific interaction between a myosin heavy chain and its associated light chains. This binding is fundamental to the assembly, stability, and regulation of myosin complexes across muscle and non-muscle cell types. Myosin light chains are not merely structural accessories; they serve as critical regulatory subunits that tune motor activity in response to cellular signals. Understanding this binding event is therefore central to deciphering how cells generate force, maintain cytoskeletal architecture, and respond to mechanical cues. In this article, we integrate the QuickGO definition with verified literature to provide a research-grade overview of GO:0032027, its key genes, disease relevance, and modern experimental approaches including CRISPR-based models.
myosin light chain binding At A Glance
| GO ID | GO:0032027 |
|---|---|
| GO term | myosin light chain binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a light chain of a myosin complex |
| Related cellular component | Myosin complex (e.g., myosin II, myosin V) |
| Related biological process | Muscle contraction, cytokinesis, cell motility |
| Key regulatory mechanism | Phosphorylation of myosin regulatory light chain |
| Disease relevance | Hypertrophic cardiomyopathy, platelet dysfunction |
What Is GO:0032027?
According to the Gene Ontology, GO:0032027 (myosin light chain binding) is defined as the binding to a light chain of a myosin complex. This molecular function describes the selective and non-covalent interaction between a protein and a myosin light chain polypeptide, which typically occurs within the context of the myosin holoenzyme. The binding is essential for the proper folding, stability, and regulatory properties of myosin motors.
Why Is myosin light chain binding Important in Cell Biology?
Myosin light chain binding is a cornerstone of mechanotransduction and motor function in eukaryotic cells. It ensures the correct assembly of myosin hexamers, modulates ATPase activity, and translates chemical signals into mechanical force. Dysregulation of this binding is implicated in cardiac hypertrophy, bleeding disorders, and other pathologies, making it a prime target for therapeutic intervention and basic research.
• Essential for the structural integrity of myosin II and myosin V complexes.
• Regulates actomyosin contractility in smooth muscle and non-muscle cells.
• Modulates cardiac thick filament mechanosensing and force generation.
• Required for integrin activation and platelet function via Myl6.
• Mutations in MYL2 and MYL3 cause hypertrophic cardiomyopathy.
• Phosphorylation of regulatory light chain controls actomyosin dissociation.
• Serves as a target for small-molecule modulators of muscle contraction.
• Provides a paradigm for studying protein-protein interaction specificity.
• Enables CRISPR-based disease modeling of sarcomeric proteins.
• Facilitates drug discovery for heart failure and bleeding disorders.
What Happens During myosin light chain binding?
Recognition and Initial Contact
In simple terms: The myosin heavy chain recognizes and grabs its light chain partner.
The binding of myosin light chains to the heavy chain is a highly specific process. Structural studies of the light chain-binding domain of myosin V reveal that the heavy chain presents an IQ motif that forms a helical platform for light chain docking. This initial recognition is driven by electrostatic and hydrophobic complementarity, ensuring that only cognate light chains are incorporated into the complex.
Stabilization of the Holoenzyme
In simple terms: Once bound, the light chain stabilizes the entire myosin molecule.
After initial contact, the light chain becomes an integral part of the myosin holoenzyme. In Drosophila nonmuscle myosin II, light chain binding is required for native stability; loss of light chain leads to heavy chain aggregation and degradation. This stabilization is critical for maintaining the lever arm architecture necessary for force transduction.
Regulatory Phosphorylation
In simple terms: Chemical tags on the light chain act as a switch for myosin activity.
The regulatory light chain (RLC) undergoes phosphorylation at specific residues, such as Ser17, which modulates actomyosin dissociation and contractility. In cardiac muscle, spatial control of RLC phosphorylation fine-tunes thick filament mechanosensing, allowing the heart to adapt to mechanical load. Myosin light chain kinase (MLCK) is a key enzyme mediating this phosphorylation in skeletal and smooth muscle.
Functional Consequences
In simple terms: Binding and its regulation determine when and how myosin generates force.
The dynamic interplay between light chain binding and phosphorylation dictates myosin ATPase activity and motor function. For example, in platelets, Myl6 binding to kindlin-3 is required for integrin αIIbβ3 activation, linking myosin light chain function to hemostasis. In cardiac muscle, mutations in MYL2 or MYL3 alter binding affinity and cause hypertrophic cardiomyopathy.
Key Genes Involved in GO:0032027 myosin light chain binding
The following genes encode myosin light chains or proteins that directly interact with them, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYL2 | Regulatory light chain of cardiac myosin | Mutations cause hypertrophic cardiomyopathy |
| MYL3 | Essential light chain of cardiac myosin | Mutations linked to cardiomyopathy |
| MYL6 | Non-muscle myosin light chain | Interacts with kindlin-3 in platelets |
| MYL9 | Regulatory light chain of smooth muscle myosin | Regulates contractility |
| MYL12A | Non-muscle regulatory light chain | Phosphorylation by MLCK |
| MYL12B | Non-muscle regulatory light chain | Actomyosin dynamics |
| MYH9 | Non-muscle myosin heavy chain IIA | Binds MYL6 and MYL12 |
| MYH10 | Non-muscle myosin heavy chain IIB | Light chain binding in neurons |
| MYO5A | Myosin V heavy chain | Light chain-binding domain structure |
| MYO5B | Myosin Vb heavy chain | Epithelial transport |
| MYLK | Myosin light chain kinase | Phosphorylates RLC |
| MYLK2 | Skeletal muscle MLCK | Regulates skeletal muscle contraction |
| MYLK3 | Cardiac MLCK | Cardiac RLC phosphorylation |
| CALM1 | Calmodulin | Activates MLCK |
| KIND3 | Kindlin-3 | Binds Myl6 in platelets |
| ITGB3 | Integrin β3 | Downstream of Myl6-kindlin-3 |
| TTN | Titin | Mechanosensing with myosin |
How Is myosin light chain binding Regulated?
Myosin light chain binding is regulated at multiple levels. Phosphorylation of the regulatory light chain by myosin light chain kinase (MLCK) is a primary regulatory mechanism; this modification alters the binding affinity and ATPase activity of myosin. In cardiac muscle, spatial control of RLC phosphorylation modulates thick filament mechanosensing, integrating mechanical and biochemical signals. Additionally, the stability of the light chain-heavy chain interaction can be influenced by associated proteins such as kindlin-3 in platelets. Calcium-calmodulin signaling activates MLCK, linking intracellular calcium levels to contractile activity.
myosin light chain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYL2 | Hypertrophic cardiomyopathy | Knock-in mouse with patient mutation |
| MYL3 | Hypertrophic cardiomyopathy | CRISPR point mutation in iPSC-CMs |
| MYL6 | Platelet dysfunction | Myl6 knockout mouse |
| MYH9 | Non-muscle myosinopathies | Knockout cell lines |
| MYO5A | Griscelli syndrome | Knock-in of light chain binding domain mutation |
Hypertrophic Cardiomyopathy
Mutations in MYL2 and MYL3, which encode cardiac myosin light chains, are well-established causes of hypertrophic cardiomyopathy (HCM). These mutations often impair light chain binding to the heavy chain, leading to sarcomeric dysfunction and compensatory hypertrophy. The molecular genetic basis of HCM highlights the critical role of myosin light chain binding in cardiac physiology.
Platelet Dysfunction and Bleeding Disorders
Myosin light chain 6 (Myl6) interacts with kindlin-3 and is required for integrin αIIbβ3 activation in platelets. Disruption of this interaction leads to defective platelet aggregation and bleeding tendencies in mouse models. This underscores the importance of myosin light chain binding beyond muscle cells.
Non-muscle Myosinopathies
In non-muscle cells, loss of light chain binding destabilizes myosin II, causing aggregation and impaired cytokinesis. Drosophila studies show that native nonmuscle myosin II stability depends on light chain binding, suggesting that similar mechanisms may underlie human diseases of cell division and migration.
From myosin light chain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of myosin light chain binding cause cardiomyopathy? | MYL2 knockout or point-mutation knock-in mouse |
| How does RLC phosphorylation affect actomyosin dynamics? | Phospho-mimetic knock-in (e.g., S17D) in cell lines |
| What is the role of Myl6 in platelet integrin activation? | Myl6 knockout mouse |
| How does light chain binding regulate myosin V cargo transport? | Tagged knock-in of MYO5A in neurons |
| Can overexpression of MYL2 rescue binding defects? | Overexpression of wild-type MYL2 in mutant cells |
| What are the structural determinants of light chain specificity? | Point mutations in the IQ motif of myosin heavy chain |
How to Study the myosin light chain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of myosin-light chain complex | Understanding binding interface |
| Pull-down assay | Protein-protein interaction | Detecting light chain binding |
| Phospho-specific Western blot | Phosphorylation of RLC | Monitoring MLCK activity |
| FRET biosensor | Conformational changes in myosin | Live-cell mechanosensing |
| CRISPR knockout | Loss of gene function | Studying essentiality of light chain |
| Knock-in point mutation | Effect of specific mutation | Modeling cardiomyopathy |
| RNA-seq | Transcriptional changes | Pathway analysis in mutant models |
| Proteomics | Protein interactions and modifications | Identifying novel light chain partners |
Structural Biology (Cryo-EM, X-ray Crystallography)
High-resolution structures of the light chain-binding domain, such as that of myosin V, reveal the molecular details of the interaction. These methods are essential for understanding how mutations alter binding affinity.
Biochemical Binding Assays
In vitro binding assays (e.g., pull-down, surface plasmon resonance) can quantify the affinity between myosin heavy chains and light chains. Such assays have been used to study the stability of nonmuscle myosin II in Drosophila.
Phosphorylation Analysis
Western blotting with phospho-specific antibodies against regulatory light chain residues (e.g., Ser17) allows monitoring of phosphorylation status, which regulates binding and actomyosin dissociation.
Live-cell Imaging
Fluorescence microscopy of tagged myosin light chains (e.g., GFP-MYL2) enables real-time visualization of myosin dynamics and mechanosensing in cardiac myocytes.
How CRISPR Can Be Used to Study GO:0032027 myosin light chain binding
Knockout
CRISPR-Cas9 knockout of myosin light chain genes (e.g., MYL2, MYL6) in cell lines or animal models can abolish binding and reveal essential functions. For example, Myl6 knockout mice exhibit platelet dysfunction. Knockout models are invaluable for assessing the requirement of light chain binding in development and disease.
Point Mutation
Introducing patient-specific point mutations (e.g., in MYL2 or MYL3) via CRISPR base editing or HDR allows precise modeling of cardiomyopathy-associated variants. Such models help dissect how single amino acid changes alter binding affinity and sarcomere function.
Knock-in
Knock-in of tagged light chains (e.g., GFP-MYL2) enables live-cell imaging of myosin dynamics. Additionally, knock-in of phospho-mimetic or phospho-deficient RLC variants (e.g., S17A, S17D) can elucidate the role of phosphorylation in binding and mechanosensing.
Overexpression
Overexpression of wild-type or mutant myosin light chains can rescue or exacerbate phenotypes in knockout backgrounds. This approach is useful for structure-function studies and for validating drug targets.
How EDITGENE Supports myosin light chain binding Research
Researchers studying myosin light chain binding-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for myosin light chain binding research.
Frequently Asked Questions About myosin light chain binding
What is myosin light chain binding?
Myosin light chain binding (GO:0032027) is a molecular function defined as binding to a light chain of a myosin complex. It is essential for myosin assembly and regulation.
What genes are involved in myosin light chain binding?
Key genes include MYL2, MYL3, MYL6, MYL9, MYL12A, MYL12B, and MYO5A, among others.
How does phosphorylation regulate myosin light chain binding?
Phosphorylation of the regulatory light chain by MLCK modulates actomyosin dissociation and contractility.
What diseases are associated with myosin light chain binding?
Mutations in MYL2 and MYL3 cause hypertrophic cardiomyopathy, and Myl6 deficiency leads to platelet dysfunction.
What is the role of myosin light chain binding in cardiac muscle?
It is critical for thick filament mechanosensing and force generation; mutations cause cardiomyopathy.
How can CRISPR be used to study myosin light chain binding?
CRISPR knockout, point mutation, and knock-in models allow precise dissection of gene function and disease mechanisms.
What experimental models are available for myosin light chain binding?
Models include knockout mice, patient-derived iPSC-cardiomyocytes, and Drosophila nonmuscle myosin II.
What methods are used to study myosin light chain binding?
Structural biology (cryo-EM), biochemical binding assays, phospho-specific Western blotting, and live-cell imaging.
Why is myosin light chain binding important for non-muscle cells?
It stabilizes nonmuscle myosin II and regulates cytokinesis and cell migration.
How does Myl6 interact with kindlin-3 in platelets?
Myl6 binds kindlin-3 and is required for integrin αIIbβ3 activation, linking myosin light chains to hemostasis.
Conclusion
Myosin light chain binding (GO:0032027) is a fundamental molecular function that underpins myosin motor assembly, regulation, and mechanotransduction. Its importance spans cardiac, skeletal, smooth, and non-muscle cells, with direct implications for hypertrophic cardiomyopathy, platelet disorders, and other diseases. Advances in CRISPR-based models and structural biology continue to illuminate the precise mechanisms of this interaction, offering new avenues for therapeutic intervention. Researchers can leverage EDITGENE's services to create tailored models and accelerate discoveries in this field.
References
- 1. Marian AJ. 2021. Molecular Genetic Basis of Hypertrophic Cardiomyopathy.. Circ Res 128(10):1533-1553 PMID: 33983830
- 2. Xu Z et al.. 2024. Myosin light chain 6 (Myl6) interacts with kindlin-3 and is required to support integrin α(IIb)β(3) activation in platelets in mice.. J Thromb Haemost 22(7):2009-2017 PMID: 38266679
- 3. Terrak M et al.. 2005. Structure of the light chain-binding domain of myosin V.. Proc Natl Acad Sci U S A 102(36):12718-23 PMID: 16120677
- 4. Cao L et al.. 2021. Phosphorylation of myosin regulatory light chain at Ser17 regulates actomyosin dissociation.. Food Chem 356:129655 PMID: 33831832
- 5. Squarci C et al.. 2026. Spatial control of myosin regulatory light chain phosphorylation modulates cardiac thick filament mechanosensing.. Proc Natl Acad Sci U S A 123(6):e2520471123 PMID: 41642989
- 6. Franke JD et al.. 2006. Native nonmuscle myosin II stability and light chain binding in Drosophila melanogaster.. Cell Motil Cytoskeleton 63(10):604-22 PMID: 16917818
- 7. Sheikh F et al.. 2015. Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease.. Gene 569(1):14-20 PMID: 26074085
- 8. Stull JT et al.. 2011. Myosin light chain kinase and the role of myosin light chain phosphorylation in skeletal muscle.. Arch Biochem Biophys 510(2):120-8 PMID: 21284933
